Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache
Information source: Sorlandet Hospital HF
Information obtained from ClinicalTrials.gov on August 08, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Headache
Intervention: prednisolone (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: Sorlandet Hospital HF Official(s) and/or principal investigator(s):
Rolf Salvesen, Professor, Study Chair, Affiliation: University of Tromso
Overall contact:
Åse D Mygland, MD, Ph.D, Phone: +4738073910, Email: aase.mygland@sshf.no
Summary
The purpose of this study is to determine whether prednisolone is more effective than placebo
in the first six days after initiation of medication withdrawal therapy for a medication
overuse headache. Another purpose is to study whether patients followed by a neurologist 1
year after withdrawal do better than patients followed by a general practitioner.
Clinical Details
Official title: Medication Overuse Headache: A Randomised Double Blind Study of Prednisolone or Placebo in Withdrawal Therapy (Phase 3), and a Randomised 1 Year Follow Up by Neurologist or General Physician After Successful Withdrawal Therapy
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Chronic daily headache and medication overuse fulfilling International Headache
Society (IHS)-II criteria
Exclusion Criteria:
- Pregnancy
- Age under 18 and over 70 years
- Major mental disorders
Locations and Contacts
Åse D Mygland, MD, Ph.D, Phone: +4738073910, Email: aase.mygland@sshf.no
Sørlandet Sykehus HF, Kristiansand, Vest-Agder 4604, Norway; Recruiting
Svein Gunnar Gundersen, Gundersen, Phone: +4738074474, Email: s.g.gundersen@sshf.no
Magne Geir Bøe, MD, Principal Investigator
Additional Information
Starting date: September 2003
Ending date: January 2007
Last updated: November 7, 2005
|
